<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
	<channel>
		<title>ADEL</title>
		<link>https://adelpharm.com</link>
		<description>ADEL, We dream of a world without dementia.</description>
		
				<item>
			<title><![CDATA[전자증권 전환 대상 주권 권리자(주주) 보호 및 조치사항 안내]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=45]]></link>
			<description><![CDATA[ 
<h2 style="text-align:center;">전자증권 전환 대상 주권 권리자(주주) 보호 및 조치사항 안내</h2>
 

 
<p style="text-align:center;">2019.09.16 「주식·사채 등의 전자등록에 관한 법률(이하 “전자증권법”)」이 시행됨에 따라
당사의 전자증권 전환 대상 주권 권리자를 보호하기 위하여 전자증권법 제27조 1항에 근거하여 아래의 사항을 통지합니다.</p>
<p style="text-align:center;"></p>
<p style="text-align:center;">– 아 래 –</p>
 
<p style="text-align:center;"><strong>1. 전자등록일(26년 06월 26일)</strong>부터 주주(권리자)가 소유중인 실물증권(전환 대상 주권)은 효력을 잃게 됩니다.</p>
<p style="text-align:center;">2.따라서, 주주(권리자)는 당사의 전자등록일<strong> 5영업일 전</strong>까지 소유중인 실물증권을 제출하고, 증권회사 계좌로 입고 신청하시기 바랍니다.</p>
<p style="text-align:center;"></p>
<p style="text-align:center;"><strong>[</strong><strong>참고]</strong> 당사(발행인)는 전자등록일<strong>(26년 06월 26일)</strong>의 직전영업일에 주주명부에 기재된 권리자를 기준으로
전자등록이 되도록 전자등록기관(한국예탁결제원)에 요청할 예정입니다.</p>
<p style="text-align:center;"><strong> </strong></p>
<p style="text-align:center;"><strong>    2026</strong><strong>년   05월  21일</strong></p>
<p style="text-align:center;"><strong>주식회사 아델</strong></p>
<p style="text-align:center;"><strong>대표이사 윤 승 용     (직인생략)</strong></p>
<p style="text-align:center;"></p>]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Thu, 21 May 2026 08:36:33 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=1"><![CDATA[notice]]></category>
		</item>
				<item>
			<title><![CDATA[South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=41]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Mon, 22 Dec 2025 14:57:50 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[사노피에 1.5조 기술 수출 치매 치료 새 접근법 제시]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=40]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Tue, 16 Dec 2025 15:24:27 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[아델, 美 학회서 타우 항체 ‘ADEL-Y01’ 임상 1a상 구두 발표]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=39]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Tue, 16 Dec 2025 15:23:28 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[아델, 존슨앤드존슨 이노베이션 JLABS 프로그램 최종 선정]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=38]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Fri, 21 Mar 2025 16:12:35 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[아델, 바디텍메드와 알츠하이머 진단제품 공동개발 나서]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=37]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Fri, 14 Feb 2025 12:52:49 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[ADEL CEO Yoon Seung-yong: "Targeting tau directly showed us the path to success against global competitors"]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=36]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Wed, 20 Nov 2024 16:52:51 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[윤승용 아델 대표 "타우 직접 타깃, 글로벌 기업과 비교해 승산 가능성 봤다"]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=35]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Tue, 19 Nov 2024 08:33:16 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[아델, '타우항체 vs경쟁 임상약물' 차별성 연구 "논문"]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=34]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Mon, 28 Oct 2024 08:27:36 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[[치매 정복 나선 K-바이오텍] ④ 아델 윤승용 대표]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=33]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Thu, 10 Oct 2024 17:37:33 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[최형진·목정하·윤승용 교수, '제22회 화이자의학상' 수상]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=32]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Mon, 07 Oct 2024 11:23:45 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[Adel raises ₩17B in series B bridge round for Alzheimer’s therapy]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=31]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Tue, 03 Sep 2024 11:09:42 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[인공지능(AI) 신약개발 시대···생존 관건 '협력']]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=30]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Fri, 09 Aug 2024 11:48:45 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[아델, AAIC에서 타우항체 신약 연구 성과 발표]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=25]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Fri, 09 Aug 2024 11:41:51 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[아델, 시리즈B 브릿지 170억원 투자 유치]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=21]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Thu, 01 Aug 2024 17:08:45 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[[벤처하는 의사들] “세계 최초 ‘타우’ 단백질 잡는 알츠하이머병 신약이 목표”]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=18]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Mon, 27 May 2024 09:51:50 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[After amyloid beta, Adel seeks next big target for Alzheimer’s]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=17]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Wed, 03 Apr 2024 16:41:50 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=16]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Mon, 26 Feb 2024 09:04:13 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[아델·오스코텍, 치매치료제 ‘ADEL-Y01’ 임상 1a상 투약 개시]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=15]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[아델 관리자]]></author>
			<pubDate>Fri, 23 Feb 2024 13:51:26 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
				<item>
			<title><![CDATA[꼴찌를 일등으로, 스트레스 질환 치료 가능성 기대]]></title>
			<link><![CDATA[https://adelpharm.com/?kboard_content_redirect=13]]></link>
			<description><![CDATA[]]></description>
			<author><![CDATA[adelpharm]]></author>
			<pubDate>Thu, 21 Sep 2023 17:24:54 +0000</pubDate>
			<category domain="https://adelpharm.com/?kboard_redirect=2"><![CDATA[press]]></category>
		</item>
			</channel>
</rss>